Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S041 - Translating Evidence into Practice: Psoriasis Guidelines

Sunday, February 18; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Develop skills to manage patients with psoriasis and psoriatic arthritis with an emphasis on decision making criteria that will enable the clinician to individualize therapy based upon disease type, extent, response to previous treatments, quality of life issues, and co-morbidities.
  • Recognize and diagnose challenging clinical cases and formulate appropriate treatment based on evidence and best practices.
  • Address gaps in clinical knowledge and care.

Description

The session will be helpful in expanding physician knowledge base and improving clinical confidence and effectiveness in treating patients with psoriasis and psoriatic arthritis. The session will consist of eight presentations and current treatment approaches and recent advances in systemic treatments for psoriasis and psoriatic arthritis including biosimilars. This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment credits. For more information about MOC, please visit the ABD website at www.abderm.org

Disclosures

  • Elmets, Craig A., MD: Aevi Genomic Medicine – SH(ST); California Association of Winegrape Growers – I(Grants/Research Funding); Elorac, Inc. – I(Grants/Research Funding); Kyowa Hakko USA – I(Grants/Research Funding); LEO Laboratories Ltd (LEO Pharma) – Data Safety Monitoring Board(Fees); Solgenix LLC – I(Grants/Research Funding);
  • Gottlieb, Alice B., MD, PhD: AbbVie – C(H), SP(H); Allergan, Inc – C(H); Beiersdorf, Inc. – A(H); BMS – A(H); Celgene Corporation – A(H); Dermira – C(H); Dr. Reddy – C(H); Eli Lilly and Company – SP(H); Incyte Corporation – C(H), I(Grants/Research Funding); Janssen Biotech – SP(H); Janssen-Ortho Inc. – A(H), I(Grants/Research Funding); Lilly ICOS LLC – C(H), I(Grants/Research Funding); Novartis – C(H), I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – C(H); UCB – A(H), I(Grants/Research Funding); Valeant Pharmaceuticals International – C(H); Valeant Pharmaceuticals North America LLC – C(H); XBiotech – C(NC);
  • Lebwohl, Mark, MD: AbbVie – I(Grants/Research Funding); Allergan, Inc. – C(H); Aqua – C(H); Arcutis, Inc. – C(H); AstraZeneca – I(Grants/Research Funding); Boehringer Ingelheim – C(H); Bristol-Myers Squibb – C(H); Celgene Corporation – I(Grants/Research Funding); Corrona, Inc. – O(H); Dr. Reddy – C(H); Eli Lilly and Company – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – O(H); Incyte Corporation – I(Grants/Research Funding); Janssen Research & Development, LLC – I(Grants/Research Funding); Leo Pharma Inc – C(H); Medimmune – I(Grants/Research Funding); Menlo Therapeutics – C(H); Mitsibushi Pharma – C(H); Neuroderm LTD – C(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); SCIderm – I(Grants/Research Funding); Theravance Biopharma – C(H); UCB – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding); Verrica Pharmaceuticals Inc – C(H); Vidac Pharma – I(Grants/Research Funding);
  • Leonardi, Craig L., MD: AbbVie – A(H), SP(H); Actavis – I(OB); Amgen – A(H), I(OB); Boehringer Ingelheim – A(H), I(OB); Celgene Corporation – I(OB), SP(H); Cellceutix – I(OB); Coherus Biosciences – I(OB); Corrona, Inc. – I(OB); Dermira – C(H), I(OB); Eli Lilly and Company – A(H), I(OB), SP(H); Glenmark Generics Inc. – I(OB); Janssen Pharmaceuticals, Inc – A(H), I(OB); Leo Pharma A/S – A(H); Leo Pharma Inc – I(OB); Novartis – SP(H); Novartis Pharmaceuticals Corp. – I(OB); Novella – I(OB); Ortho Dermatologics – A(H); Pfizer Inc. – A(H), I(OB); Sandoz, a Novartis company – A(H), I(OB); Sienna Biopharmaceuticals – I(OB); Sun Pharmaceutical Industries Ltd. – SP(H); UCB – A(H), I(OB);
  • Lim, Henry W., MD: Estee Lauder – I(Grants/Research Funding); Ferndale Laboratories, Inc. – I(Grants/Research Funding); Incyte Corporation – I(Grants/Research Funding); Unigen – I(Grants/Research Funding);
  • Menter, Alan, MD: AbbVie – A(H), C(H), I(Grants/Research Funding), SP(H); Afecta Pharmaceuticals – A(NC), C(NC); Amgen – A(Grants/Research Funding), C(H), I(Grants/Research Funding), SP(H); Boehringer Ingelheim – A(H), I(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding); Eli Lilly and Company – A(H), C(H), I(Grants/Research Funding), I(H); Galderma USA – C(H); Janssen Biotech – SP(H); Janssen Pharmaceuticals, Inc – A(H), C(H), I(Grants/Research Funding); LEO Pharma, US – A(H), C(H), SP(H); Medimetriks Pharmaceuticals, Inc. – I(Grants/Research Funding); Medscape – A(H); Menlo Therapeutics – C(H); Merck & Co., Inc – I(Grants/Research Funding); New Enterprise Associates – C(Fees); Novartis – C(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding), SP(H); Prime Education – Independent Contractor(Fees); Promius Pharma, LLC – C(Fees), SP(H); Sienna Biopharmaceuticals – C(H); Spherix Global Insights US, Inc. – C(Fees); Valeant Pharmaceuticals North America LLC – C(Fees); Wyeth Labs – C(H), SP(H);
Schedule
Sunday, February 18
1:00 PM
Dr. Menter and Dr. Elmets / Introduction/Dr. Menter and Dr. Elmets
1:10 PM
Dr. Elmets / Current Concepts in Psoriasis Pathogenesis
1:30 PM
Dr. Lebwohl / Systemic Therapies for Psoriasis and Psoriatic Arthritis with Case Studies
1:50 PM
Dr. Lim / Phototherapy for Psoriasis with Case Studies
2:10 PM
Dr. Gottlieb / Current and Emerging Biologic Therapies for Psoriatic Arthritis
2:30 PM
Dr. Leonardi / Current Biologic Therapies for Psoriasis with Case Studies
2:50 PM
Dr. Menter / Emerging Biologic Therapies for Psoriasis
3:10 PM
Dr. Gelfand / Psoriasis Co-Morbidities and Prevention of Risk Factors
3:40 PM
Dr. Menter / Panel Discussion
Event Details
  • Date
    Sunday, February 18
  • Time
    1:00 PM - 4:00 PM
  • Location
    Ballroom 20A
  • CME Credits
    3.00
  • Type
    MOC
Directors/Co-Directors
  • Alan Menter, MD, FAAD - Handout
  • Craig A. Elmets, MD, FAAD
Speakers
  • Alice B. Gottlieb, MD, PhD, FAAD - Handout
  • Craig L. Leonardi, MD, FAAD
  • Henry W. Lim, MD, FAAD - Handout
  • Mark Lebwohl, MD, FAAD - Handout